Please login to the form below

paclitaxel

This page shows the latest paclitaxel news and features for those working in and with pharma, biotech and healthcare.

BMS’ Opdivo wins EU approval for second-line oesophageal cancer

The EC approved Opdivo following positive results from the phase 3 ATTRACTION-3 trial, which investigated the PD-1 inhibitor versus chemotherapy docetaxel or paclitaxel – as a treatment for patients with

Latest news

Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq plus paclitaxel failed to improve progression-free survival. Roche’s hopes of extending its PD-L1 inhibitor Tecentriq into metastatic triple negative breast cancer (TNBC) have fallen flat after the ... The phase 3 Impassion131 study evaluated
Tecentriq misses the mark in advanced ovarian cancer

The phase 3 IMagyn050 study evaluated the addition of Tecentriq (atezolizumab) to Roche’s older treatment Avastin (bevacizumab) alongside chemotherapy (paclitaxel and carboplatin) in women with advanced-stage ovarian cancer.
Immutep slumps on latest efti data in breast cancer

specifically paclitaxel. ... That could suggest the effect of efti is enhanced by some property of chemo, such as increased inflammation during treatment with paclitaxel.
AZ’s comeback drug cediranib stumbles in phase 3 trial

Last year, Lynparza plus cediranib also failed to show a statistically significant improvement over standard chemotherapy with paclitaxel in patients with platinum-resistant ovarian cancer in the BAROCCO study, which included
BMS scores first oesophageal cancer nod for Opdivo in Japan

The MHLW approved Opdivo based on the results from the phase 3 ATTRACTION-3 trial, which evaluated the PD-1 inhibitor versus chemotherapy – docetaxel or paclitaxel – as a treatment for patients

More from news
Approximately 9 fully matching, plus 119 partially matching documents found.

Latest Intelligence

Immuno-oncology in 2019: the rapid evolution continues

An FDA ruling on Tecentriq in combination with carboplatin and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic non-squamous NSCLC (based on the IMpower130 trial) is
Pharma deals in May 2015

Sorrento (Igdrasol)/ NantPharma. Asset acquisition. Acquisition of Igdrasol including Cynviloq (paclitaxel nanoparticle).
The rise of chronic disease in BRIC markets

For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

BMS appoints oncology development head

Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer

Current chemotherapy treatment options for ovarian cancer are fairly standard. After debulking surgery, the patient will undergo their first line of chemotherapy; the standard of care involves a combination of paclitaxel

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Medical Editor: Competitive Salary

Senior Account Manager/ Account Director: Competitive Salary Offered

Senior Medical Writer: Competitive Salary

Associate Account Director: Competitive Salary

Account Management: Competitive Salary Offered

Editorial Traffic Manager, Medical Communications Agency, London...: up to £45K

Senior & Principal Medical Writer: Competitive Salary Offered

Publications Director: Competitive Salary

Medical Writers (All levels) Editorial / Scientific Leads & ...: Highly Competitive Remuneration packages

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Head of Strategic Planning, Healthcare Advertising/ Brand comms,...: Six figure salary

Account Manager: Competitive Salary

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Account Manager - Creative Healthcare Communications - South Wes...: Excellent Remuneration

Senior & Principal Medical Writers Medical Communications - ...: Salary TBC

Group Account Director, Healthcare Advertising/ Brand comms, Lon...: 8 month contract up to £90K

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Account Executive: Competitive Salary

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?: Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials: Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity: Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....

Email:
Password:

Please login to the form below

paclitaxel

COVID-19 Updates and Daily News

Featured jobs

Quick links